Mesa Laboratories (NASDAQ:MLAB) PT Lowered to $106.00 at Evercore ISI

Mesa Laboratories (NASDAQ:MLAB) had its price target dropped by Evercore ISI from $120.00 to $106.00 in a report issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Evercore ISI’s price objective indicates a potential upside of 19.87% from the stock’s previous close.

Mesa Laboratories Trading Down 0.0 %

Shares of Mesa Laboratories stock traded down $0.02 on Tuesday, reaching $88.43. The company had a trading volume of 3,472 shares, compared to its average volume of 46,882. The firm’s 50-day moving average price is $104.77 and its two-hundred day moving average price is $102.85. Mesa Laboratories has a 1 year low of $82.86 and a 1 year high of $145.46. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.37 and a quick ratio of 1.86. The firm has a market cap of $476.64 million, a price-to-earnings ratio of -1.88 and a beta of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Wednesday, June 5th. The medical instruments supplier reported $2.25 earnings per share (EPS) for the quarter. Mesa Laboratories had a positive return on equity of 10.10% and a negative net margin of 117.61%. The company had revenue of $58.90 million during the quarter. As a group, research analysts predict that Mesa Laboratories will post 6.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MLAB. Boone Capital Management LLC acquired a new position in Mesa Laboratories during the 4th quarter valued at about $6,712,000. Motley Fool Asset Management LLC grew its stake in Mesa Laboratories by 643.8% during the 1st quarter. Motley Fool Asset Management LLC now owns 64,776 shares of the medical instruments supplier’s stock valued at $7,108,000 after purchasing an additional 56,067 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in Mesa Laboratories by 9.1% during the 4th quarter. Conestoga Capital Advisors LLC now owns 578,463 shares of the medical instruments supplier’s stock valued at $60,606,000 after purchasing an additional 48,253 shares during the last quarter. Comerica Bank purchased a new stake in Mesa Laboratories during the 3rd quarter valued at about $4,849,000. Finally, Glenmede Trust Co. NA grew its stake in Mesa Laboratories by 87.4% during the 3rd quarter. Glenmede Trust Co. NA now owns 94,337 shares of the medical instruments supplier’s stock valued at $9,912,000 after purchasing an additional 44,002 shares during the last quarter. 90.60% of the stock is owned by institutional investors and hedge funds.

About Mesa Laboratories

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.